

(M)

with a strong base to produce an anion; and

reacting said anion with a suitable Michael acceptor.

Remarks

Claims 1-17, 19-20, 24-26, and 28-37 are pending. The specification was amended to correct obvious, typographical errors. One of skill in the art would understand that recitation of "$CH_2(CH_3)_2$" is clearly a typographical error and instead should read as "$CH(CH_3)_2$." Support for these changes can be found in Applicant's original specification, particularly at page 4, lines 19-24, in the table at page 8, in the table at page 9, in the table at page 79, and in the table at page 81. No new matter is added.

Additionally, the specification has been amended to correct an obvious error in the description of the compounds of formula (I). Support for the addition of "pyridylC_{1-2}alkyl, imidazolylC_{1-2}alkyl" to the description of R^7 can be found in Applicant's original specification, particularly at page 10, lines 20-25, page 11, line 6, Example Ib-5 at page 51, Example Ib-6 at page 51, and Example Ib-8 at page 52. No new matter is added.

Claim 18 was cancelled and rewritten as new Claim 31. Claim 27 was cancelled and rewritten as new Claim 37. Claims 21-23 have been cancelled. Claim 1 was amended to correct the clerical error described in the preceding paragraph with respect to the amendments to the specification. No new matter is added.

Claims 2-5 were amended to correct an obvious, typographical error. Support for this amendment can be found in Applicant's original specification, particularly at page 4, lines 19-24, in the table at page 8, in the table at page 9, and page 20, line 25. No new matter is added.

Claim 13 was amended to correct an obvious, typographical error. Support for this amendment can be found in Applicant's original specification, particularly at page 3, line 13, and page 10, line 23. No new matter is added.

Claims 31-37 have been added to complete the record. Support for these claims can be found in Applicant's original specification, particularly at page 69, lines 3-31, pages 3-14, page 69, and pages 21-22. No new matter is added.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222 to discuss this case further, if desired.

Respectfully submitted,



Lorie Ann Morgan, Esq.
Reg. No. 38,181

31 Oct '01

GlaxoSmithKline, Inc.
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709

Marked-up Copy of Specification

Page 5, lines 9-20:

W is H;

X is CH_2 or NH; n is 1;

Y is CH_2; m is 0 or 1, provided that if X is CH_2, n is 1 and m is 0, then R^1 is not CH_2CH_3;

Z is O; p is 0 or 1;

R^1 is H, CH_3, CH_2CH_3, $(CH_2)_2CH_3$, $(CH_2)_3CH_3$, $[CH_2(CH_3)_2]$ $\underline{CH(CH_3)_2}$, $CH_2CH(CH_3)_2$, $C(CH_3)_3$, benzyl, 4-pyridylmethyl or 3-pyridylmethyl;

R^2 is phenyl, 2-fluorophenyl, 2-chlorophenyl or 2-pyridyl;

R^3 is Cl, Br or NO_2;

R^4 is H, CH_3 or $CH_2CH_2N(CH_2CH_3)_2$;

R^5 and R^6 together are O or S; or

pharmaceutically acceptable salts and solvates thereof.

Page 5, line 22 and continuing to page 6, line 9:

W is H;

X is CH_2 or NH; n is 1;

Y is CH_2; m is 1;

p is 0;

R^1 is H, CH_3, CH_2CH_3, $(CH_2)_2CH_3$, $(CH_2)_3CH_3$, $[CH_2(CH_3)_2]$ $\underline{CH(CH_3)_2}$, $CH_2CH(CH_3)_2$, $C(CH_3)_3$, benzyl, 4-pyridylmethyl or 3-pyridylmethyl; provided that if R^1 is 3-pyridylmethyl or 4-pyridylmethyl, then X is CH_2, n is 1, Y is CH_2, m is 0 or 1, R^2 is 2-fluorophenyl, R^3 is Cl, R^4 is H and R^5 and R^6 together is oxygen;

R^2 is phenyl, 2-fluorophenyl, 2-chlorophenyl or 2-pyridyl,

R^3 is Cl, Br or NO_2;

R^4 is H, CH_3 or $CH_2CH_2N(CH_2CH_3)_2$; provided that when R^4 $CH_2CH_2N(CH_2CH_3)_2$, then X is CH_2, n is 1, Y is CH_2, m is 1, R^1 is CH_3 or benzyl, R^2 is 2-fluorophenyl, R^3 is Cl and R^5 and R^6 together represent O;

R^5 and R^6 together are O or S; or

pharmaceutically acceptable salts and solvates thereof.

Page 6, lines 12-23:

W is H;

X is CH_2 or NH; n is 1;

Y is CH_2; m is 0 or 1, provided that if X is CH_2 and m is 0, then R^1 is not CH_2CH_3;

p is 0;

R^1 is CH_3, CH_2CH_3, $(CH_2)_2CH_3$, $(CH_2)_3CH_3$, $[CH_2(CH_3)_2]$ $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $C(CH_3)_3$, benzyl or 4-pyridylmethyl;

R^2 is 2-fluorophenyl, 2-chlorophenyl or 2-pyridyl,

R^3 is Cl, Br or NO_2;

R^4 is H, CH_3 or $CH_2CH_2N(CH_2CH_3)_2$;

R^5 and R^6 together are O or S; or

pharmaceutically acceptable salts and solvates thereof.

Paragraph beginning on page 6, line 25 and continuing to page 7, line 9:

W is H;

X is CH_2 or NH; n is 1;

Y is CH_2; m is 0 or 1, provided that if X is CH_2 and m is 0, then R^1 is not CH_2CH_3;

p is 0;

R^1 is CH_3, CH_2CH_3, $(CH_2)_2CH_3$, $(CH_2)_3CH_3$, $[CH_2(CH_3)_2]$ $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $C(CH_3)_3$, benzyl or 4-pyridylmethyl; provided that when R^1 is 4-pyridylmethyl, X is CH_2, Y is CH_2, m is 1, R^2 is 2-fluorophenyl, R^3 is Cl, R^4 is H and R^5 and R^6 together represent oxygen;

R^2 is 2-fluorophenyl, 2-chlorophenyl or 2-pyridyl,

R^3 is Cl, Br or NO_2;

R^4 is H, CH_3 or $CH_2CH_2N(CH_2CH_3)_2$; provided that when R^4 is $CH_2CH_2N(CH_2CH_3)_2$, then X is CH_2, Y is CH_2, m is 1, R^1 is CH_3 or benzyl, R^2 is 2-fluorophenyl, R^3 is Cl and R^5 and R^6 together represent O;

R^5 and R^6 together represent O or S; or

pharmaceutically acceptable salts and solvates thereof.

Paragraph on page 3, lines 5-25:

wherein

W is H or C_1-C_4 branched alkyl or a straight chained alkyl;

X is CH_2, NH, or NCH_3; n is 1 or 2;

Y is O, CH_2; m is 0 or 1, provided that if X is CH_2, n is 1 and m is 0, then R^1 is not CH_2CH_3;

Z is O; p is 0 or 1;

R^1 is H, a C_1-C_7 straight chain alkyl, a C_3-C_7 branched chain alkyl, a C_1-C_4 haloalkyl, a C_3-C_7 cycloalkyl, an aryl, a heteroaryl, an aralkyl, or a heteroaralkyl;

R^2 is phenyl, 2-halophenyl or 2-pyridyl,

R^3 is H, Cl, Br, F, I, CF_3 or NO_2;

(1) R^4 is H, C_1-C_4 alkyl, or dialkylaminoalkyl and R^5 and R^6 together represent a single oxygen or S atom which is linked to the diazepine ring by a double bond and p is zero or 1 (as depicted in formula Ia); or (2) R^4 and R^5 together form a double bond in the diazepine ring and R^6 represents the group NHR^7 wherein R^7 is H, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, pyridylC_{1-2}alkyl, imidazolylC_{1-2}alkyl, benzyl or benzyl mono or disubstituted independently with halogen substituents, C_{1-4}alkylpyridyl or C_{1-4} alkylimidazolyl and p is zero (as depicted in formula Ib);

or (3) R^4, and R^6 form the group $-CR^8=U-V=$ wherein R^8 is hydrogen, C_{1-4} alkyl, or C_{1-3} hydroxyalkyl, U is N or CR^9 wherein R^9 is H, C_{1-4}alkyl, C_{1-3}hydroxyalkyl or C_{1-4}alkoxy- C_{1-4}alkyl, V is N or CH and p is zero (as depicted in formula Ic);

or pharmaceutically acceptable salts and or solvates thereof.

Marked-up Copy of Amended Claims

1. (Amended) A compound of formula (I):



Formula (I)

wherein

W is H, a C_1-C_4 branched alkyl, or straight chained alkyl;

X is CH_2, NH or NCH_3; n is 1 or 2;

Y is O or CH_2; m is 0 or 1, provided that if X is CH_2, n is 1 and m is 0, then R^1 is not CH_2CH_3;

Z is O; p is 0 or 1;

R^1 is H, a C_1-C_7 straight chain alkyl, a C_3-C_7 branched chain alkyl, a C_1-C_4 haloalkyl, a C_3-C_7 cycloalkyl, an aryl, a heteroaryl, an aralkyl, or a heteroaralkyl;

R^2 is phenyl, 2-halophenyl or 2-pyridyl,

R^3 is H, Cl, Br, F, I, CF_3 or NO_2; and wherein

(1) R^4 is H, a C_1-C_4 alkyl, or a dialkylaminoalkyl and R^5 and R^6 together represent a single oxygen or S atom which is linked to the diazepine ring by a double bond and p is zero or 1; or (2) R^4 and R^5 together is a double bond in

the diazepine ring and R^6 represents the group NHR^7 wherein R^7 is H, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, pyridylC_{1-2}alkyl, imidazolylC_{1-2}alkyl, benzyl, [or] benzyl mono or disubstituted independently with halogen substituents, C_{1-4}alkylpyridyl or C_{1-4} [alkylimidazolyl] alkylimidazolyl and p is zero;
or (3) R^4, R^5 and R^6 form the group $-CR^8=U-V=$ wherein R^8 is hydrogen, C_{1-4} alkyl or C_{1-3} hydroxyalkyl, U is N or CR^9 wherein R^9 is H, C_{1-4}alkyl, C_{1-3}hydroxyalkyl or C_{1-4}alkoxy, C_{1-4}alkyl, V is N or CH and p is zero; [or] and pharmaceutically acceptable salts [and] or solvates thereof.

2. (Amended) A compound according to claim 1 wherein
W is H;
X is CH_2 or NH; n is 1;
Y is CH_2; m is 0 or 1, provided that if X is CH_2, n is 1 and m is 0, then R^1 is not CH_2CH_3;
Z is O; p is 0 or 1;
R^1 is H, CH_3, CH_2CH_3, $(CH_2)_2CH_3$, $(CH_2)_3CH_3$, $[CH_2(CH_3)_2]$ $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $C(CH_3)_3$, benzyl, 4-pyridylmethyl or 3-pyridylmethyl;
R^2 is phenyl, 2-fluorophenyl, 2-chlorophenyl or 2-pyridyl;
R^3 is Cl, Br or NO_2;
R^4 is H, CH_3 or $CH_2CH_2N(CH_2CH_3)_2$;
R^5 and R^6 together are either O or S; [or] and
pharmaceutically acceptable salts [and] or solvates thereof.

3. (Amended) A compound according to claim 1 wherein
W is H;
X is CH_2 or NH; n is 1;
Y is CH_2; m is 1;
p is 0;
R^1 is H, CH_3, CH_2CH_3, $(CH_2)_2CH_3$, $(CH_2)_3CH_3$, $[CH_2(CH_3)_2]$ $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $C(CH_3)_3$, benzyl, 4-pyridylmethyl or 3-pyridylmethyl; provided that if R^1 is 3-pyridylmethyl or 4-pyridylmethyl, then X is CH_2, n is 1, Y is CH_2, m is 0 or 1, R^2 is 2-fluorophenyl, R^3 is Cl, R^4 is H and R^5 and R^6 together are O;

R^2 is phenyl, 2-fluorophenyl, 2-chlorophenyl or 2-pyridyl,

R^3 is Cl, Br or NO_2;

R^4 is H, CH_3 or $CH_2CH_2N(CH_2CH_3)_2$; provided that when R^4 $CH_2CH_2N(CH_2CH_3)_2$, X is CH_2, n is 1, Y is CH_2, m is 1, R^1 is CH_3 or benzyl, R^2 is 2-fluorophenyl, R^3 is Cl and R^5 and R^6 together is O;

R^5 and R^6 together are O or S; [or] and

pharmaceutically acceptable salts [and] or solvates thereof.

4. (Amended) A compound according to claim 1 wherein

W is H;

X is CH_2 or NH; n is 1;

Y is CH_2; m is 0 or 1, provided that if X is CH_2 and m is 0, then R^1 is not CH_2CH_3;

p is 0;

R^1 is CH_3, CH_2CH_3, $(CH_2)_2CH_3$, $(CH_2)_3CH_3$, $[CH_2(CH_3)_2]$ $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $C(CH_3)_3$, benzyl or 4-pyridylmethyl;

R^2 is 2-fluorophenyl, 2-chlorophenyl or 2-pyridyl,

R^3 is Cl, Br or NO_2;

R^4 is H, CH_3 or $CH_2CH_2N(CH_2CH_3)_2$;

R^5 and R^6 together [is] are O or S; [or] and

pharmaceutically acceptable salts [and] or solvates thereof.

5. (Amended) A compound according to claim 1 wherein

W is H;

X is CH_2 or NH; n is 1;

Y is CH_2; m is 0 or 1, provided that if X is CH_2 and m is 0, then R^1 is not CH_2CH_3;

p is 0;

R^1 is CH_3, CH_2CH_3, $(CH_2)_2CH_3$, $(CH_2)_3CH_3$, $[CH_2(CH_3)_2]$ $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $C(CH_3)_3$, benzyl or 4-pyridylmethyl; provided that when R^1 is 4-pyridylmethyl, then X is CH_2, n is 1, Y is CH_2, m is 1, R^2 is 2-fluorophenyl, R^3 is Cl, R^4 is H and R^5 and R^6 together [is] are O;

R^2 is 2-fluorophenyl, 2-chlorophenyl or 2-pyridyl,

R^3 is Cl, Br or NO_2;

R^4 is H, CH_3 or $CH_2CH_2N(CH_2CH_3)_2$; provided that when R^4 is $CH_2CH_2N(CH_2CH_3)_2$, X is CH_2, n is 1, Y is CH_2, m is 1, R^1 is CH_3 or benzyl, R^2 is 2-fluorophenyl, R^3 is Cl and R^5 and R^6 together [is] are O;

R^5 and R^6 together are O or S; [or] and

pharmaceutically acceptable salts [and] or solvates thereof.

6. (Amended) A compound according to claim 1 wherein [in each compound] W is H and [wherein] X, n, Y, m, Z, p and R^{1-6} for each compound are as follows:

X	n	Y	M	Z	p	R^1	R^2	R^3	R^4	R^5R^6
CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	Cl	H	O
CH_2	1	--	0	--	0	CH_3	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	Br	H	O
CH_2	1	CH_2	1	--	0	benzyl	2-fluorophenyl	Cl	H	O
CH_2	1	--	0	--	0	benzyl	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-chlorophenyl	Cl	H	O
CH_2	1	CH_2	2	--	0	CH_3	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	benzyl	2-pyridyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-pyridyl	Br	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-pyridyl	Cl	H	O
CH_2	1	CH_2	2	--	0	$C(CH_3)_3$	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	NO_2	H	O
CH_2	1	CH_2	1	--	0	$(CH_2)_2CH_3$	2-pyridyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_2CH_3	2-pyridyl	Cl	H	O
CH_2	1	CH_2	1	--	0	4-pyridylmethyl	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	$(CH_2)_3CH_3$	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	$(CH_2)_3CH_3$	2-pyridyl	Cl	H	O
CH_2	1	CH_2	1	--	0	$CH_2CH(CH_3)_2$	2-pyridyl	Cl	H	O
CH_2	1	--	0	--	0	CH_2CH_3	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	$CH(CH_3)_2$	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	Cl	$CH_2CH_2N(CH_2CH_3)_2$	O

CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	Cl	CH_3	O
CH_2	1	--	0	--	0	benzyl	2-fluorophenyl	Cl	CH_3	O
CH_2	1	CH_2	1	--	0	benzyl	2-fluorophenyl	Cl	$CH_2CH_2N(CH_2CH_3)_2$	O
NH	1	CH_2	1	--	0	CH_3	2-chlorophenyl	Cl	H	O
NH	1	CH_2	2	--	0	CH_3	2-chlorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	Cl	H	S
CH_2	1	CH_2	1	--	0	CH_3	2-chlorophenyl	Cl	H	S
CH_2	1	CH_2	1	--	0	CH_3	2-pyridyl	Cl	H	S
CH_2	1	CH_2	1	O	1	CH_3	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	benzyl	phenyl	NO_2	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	H	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-pyridyl	NO_2	H	O
CH_2	1	CH_2	1	--	0	benzyl	2-pyridyl	NO_2	H	O
CH_2	1	CH_2	1	--	0	benzyl	2-fluorophenyl	H	H	O
CH_2	1	CH_2	1	--	0	CH_3	phenyl	NO_2	H	O
NH	1	CH_2	2	--	0	$(CH_2)_3CH_3$	2-fluorophenyl	Cl	H	O
CH_2	1	--	0	--	0	3-pyridylmethyl	2-fluorophenyl	Cl	H	O
CH_2	1	--	0	--	0	4-pyridylmethyl	2-fluorophenyl	Cl	H	O.

7. (Amended) A compound according to claim 1 wherein [in each compound] W is H and [wherein] X, n, Y, m, Z, p and R^{1-6} for each compound are as follows:

X	n	Y	M	Z	p	R^1	R^2	R^3	R^4	R^5R^6
CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	Cl	H	O
CH_2	1	--	0	--	0	CH_3	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	Br	H	O
CH_2	1	CH_2	1	--	0	benzyl	2-fluorophenyl	Cl	H	O
CH_2	1	--	0	--	0	benzyl	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-chlorophenyl	Cl	H	O
CH_2	1	CH_2	2	--	0	CH_3	2-fluorophenyl	Cl	H	O

CH_2	1	CH_2	1	--	0	benzyl	2-pyridyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-pyridyl	Br	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-pyridyl	Cl	H	O
CH_2	1	CH_2	2	--	0	$C(CH_3)_3$	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	NO_2	H	O
CH_2	1	CH_2	1	--	0	$(CH_2)_2CH_3$	2-pyridyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_2CH_3	2-pyridyl	Cl	H	O
CH_2	1	CH_2	1	--	0	4-pyridylmethyl	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	$(CH_2)_3CH_3$	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	$(CH_2)_3CH_3$	2-pyridyl	Cl	H	O
CH_2	1	CH_2	1	--	0	$CH_2CH(CH_3)_2$	2-pyridyl	Cl	H	O
CH_2	1	--	0	--	0	CH_2CH_3	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	$CH(CH_3)_2$	2-fluorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	Cl	$CH_2CH_2N(CH_2CH_3)_2$	O
CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	Cl	CH_3	O
CH_2	1	--	0	--	0	benzyl	2-fluorophenyl	Cl	CH_3	O
CH_2	1	CH_2	1	--	0	benzyl	2-fluorophenyl	Cl	$CH_2CH_2N(CH_2CH_3)_2$	O
NH	1	CH_2	1	--	0	CH_3	2-chlorophenyl	Cl	H	O
NH	1	CH_2	2	--	0	CH_3	2-chlorophenyl	Cl	H	O
CH_2	1	CH_2	1	--	0	CH_3	2-fluorophenyl	Cl	H	S
CH_2	1	CH_2	1	--	0	CH_3	2-chlorophenyl	Cl	H	S
CH_2	1	CH_2	1	--	0	CH_3	2-pyridyl	Cl	H	S
CH_2	1	CH_2	1	O	1	CH_3	2-fluorophenyl	Cl	H	O.

8. (Amended) A compound according to claim 1 wherein [in each compound] W is H, [and] p is 0, and [wherein] X, n, Y, m, R^{1-5} for each compound are as follows:

X	n	Y	m	R^1	R^2	R^3	R^4	R^5 and R^6
CH_2	1	CH_2	1	CH_3	2-fluorophenyl	Cl	H	O

CH_2	1	CH_2	1	CH_3	2-fluorophenyl	Br	H	O
CH_2	1	CH_2	1	CH_3	2-pyridyl	Cl	H	O
CH_2	1	CH_2	1	CH_3	2-fluorophenyl	Cl	CH_3	O.

9. (Amended) A compound according to claim 1 wherein W is H, X is CH_2, n is 1, Y is CH_2, m is 1, p is 0, R^1 is CH_3, R^2 is 2-fluorophenyl, R^3 is Cl, R^4 is H and R^5 and R^6 together [is] are O.

12. (Amended) A compound according to claim 10, wherein [in each compound] W is H, X is CH_2, n is 1, Y is CH_2, m is 1, R^1 is CH_3, and [wherein] R^2, R^3 and R^7 [for each compound] are as follows:

R^2	R^3	R^7
2-fluorophenyl	Cl	CH_3
2-pyridyl	Cl	CH_3
2-fluorophenyl	Cl	CH_2CH_3
2-fluorophenyl	Cl	benzyl
2-fluorophenyl	Cl	4-pyridylmethyl
2-fluorophenyl	Cl	4-pyridylethyl
2-fluorophenyl	Cl	$CH_2CH(CH_3)_2$
2-fluorophenyl	Cl	2-(4-imidazolyl)ethyl
2-fluorophenyl	Cl	CH_2CH_2OH
2-fluorophenyl	Br	CH_3
2-chlorophenyl	Cl	CH_3 .

13. (Amended) A compound according to claim 10, wherein [in each compound] W is H, X is CH_2, n is 1, Y is CH_2, m is 1, R^1 is CH_3, [R^3] R^2 is 2-fluorophenyl, R^3 is chlorine or bromine and R^7 is methyl.

15. (Amended) A compound [of] according to claim 1 wherein p is zero and R^4, R^5 and R^6 together form the group $-C(R^8)=U-V=$.

19. (Amended) A compound according to claim 15, wherein [in each compound] W is H, X is CH_2, n is 1, Y is CH_2, m is 1 and [wherein] R^1, R^2, R^3, R^8, U and V [for each compound] are as follows:

R^1	R^2	R^3	R^8	U	V
CH_3	2-pyridyl	Br	CH_3	CH	N
CH_3	2-pyridyl	Cl	CH_3	CH	N
CH_3	2-fluorophenyl	Cl	CH_3	N	CH
CH_3	2-pyridyl	Br	H	C-CH_3	N.

20. (Amended) A compound according to claim 15, wherein [in] W is H, X is CH_2, n is 1, Y is CH_2, m is 1, R^1 is CH_3, R^2 is 2-pyridyl, R^3 is Br, R^8 is CH_3, U is CH and V is N.

24. (Amended) A method of producing sedation or hypnosis, inducing anxiolysis, inducing muscle relaxation [in a mammal] or treating convulsions in a mammal which comprises administering to the mammal an effective amount of a compound of claim 1.

25. (Amended) A method of producing sedation or hypnosis, inducing anxiolysis, inducing muscle relaxation [in a mammal] or treating convulsions in a mammal which comprises administering to the mammal an effective amount of a compound of claim 10.

26. (Amended) A method of producing sedation or hypnosis, inducing anxiolysis, inducing muscle relaxation [in a mammal] or treating convulsions in a mammal which comprises administering to the mammal an effective amount of a compound of claim 15.